MEI Pharma Inc
NASDAQ:MEIP
MEI Pharma Inc
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The company went IPO on 2003-12-18. The firm is focused on development and commercialization of novel cancer therapies. The firm's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The firm is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS).
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The company went IPO on 2003-12-18. The firm is focused on development and commercialization of novel cancer therapies. The firm's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The firm is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS).
Pipeline Focus: MEI Pharma is moving forward independently with its two lead clinical-stage oncology programs, voruciclib and ME-344, following the termination of the Infinity merger.
Clinical Milestones: Data readouts are expected for voruciclib in early 2024 and for ME-344 in the first half of 2024.
Financial Position: MEI reported $100.7 million in cash, cash equivalents, and short-term investments as of June 30, 2023, with no debt, and expects this to fund operations for at least the next 12 months.
Program Progress: Both voruciclib and ME-344 have shown promising early clinical activity and good tolerability in ongoing Phase 1 and 1b studies.
Market Opportunity: Management highlighted significant addressable markets for their drug candidates, referencing the multibillion-dollar sales of comparator drugs (venetoclax and bevacizumab).
Activist Investors: The company acknowledged ongoing discussions with activist stockholders Anson and Cable Car, who have proposed director candidates.
